Medicilon(SH:688202) Xin Lang Cai Jing·2025-11-13 02:16Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Meidi Xi, indicating a significant increase in stock price and trading activity [1][2] - As of November 13, Meidi Xi's stock price rose by 2.06% to 67.96 CNY per share, with a total market capitalization of 9.131 billion CNY [1] - Year-to-date, Meidi Xi's stock has increased by 125.26%, with a 2.43% rise in the last five trading days and a 10.50% increase over the past 20 days [1] Group 2 - Meidi Xi operates in the pharmaceutical and biotechnology sector, specifically in medical services and drug research outsourcing, with a revenue composition of 50.34% from preclinical research and 49.64% from drug discovery and pharmaceutical research [2] - For the period from January to September 2025, Meidi Xi reported a revenue of 843 million CNY, reflecting a year-on-year growth of 5.14%, while the net profit attributable to shareholders was -29.6849 million CNY, showing a significant increase of 76.93% [2] - The company has distributed a total of 158 million CNY in dividends since its A-share listing, with 33.9365 million CNY distributed over the past three years [3]